Your proposal is forming. Every pick moves the live mandate bar.
Closed · 1 votes · Generated by the Sage
Status and record
Insulin and Essential Drug Affordability Act
Citizen bill draft · Federal · Full civic synthesis · Closed · 1 votes
THE PROBLEM: Citizens in this signal (684 score, 6 voices) describe a consistent crisis: insulin costing $300/month forces rationing and skipped doses, especially for people on fixed incomes. Citizens note the same drugs cost a fraction of U.S. prices abroad, that insurers deny prescriptions, and that annual price hikes occur without clear justification. One voice raised concern about pharmaceutical campaign donations influencing votes. These signals point to two linked issues: high out-of-pocket drug costs and a lack of transparency in pricing. PROPOSED PROVISIONS: 1. CAP INSULIN COPAYS: Limit out-of-pocket cost for insulin to $35 per month per covered patient across all regulated insurance plans, with no deductible required first. 2. EMERGENCY ACCESS: Establish a pharmacy-level emergency supply program allowing a person to obtain up to a 30-day insulin supply without prior authorization when they would otherwise go without. 3. PRICE TRANSPARENCY: Require manufacturers to publicly justify any list-price increase above the rate of inflation for drugs designated as essential, filing the reason with the relevant health agency. 4. INFLATION-LINKED REBATES: Require manufacturers that raise prices on essential drugs faster than inflation to pay a rebate to the public health program, reducing taxpayer cost. 5. INTERNATIONAL PRICE REFERENCE STUDY: Direct the health agency to publish an annual comparison of U.S. prices for the top 50 essential drugs against prices in peer countries, to inform future negotiation authority. 6. PRIOR-AUTHORIZATION REFORM: Require insurers to respond to prescription prior-authorization requests for essential chronic-condition drugs within 72 hours, and within 24 hours for urgent cases, or the request is automatically approved. 7. ESSENTIAL DRUG LIST: Create a defined, periodically updated list of essential drugs (insulin, inhalers, and other maintenance medications) to which these protections apply. WHO BENEFITS: People with diabetes and other chronic conditions, particularly those on fixed incomes or paying high copays. Patients facing repeated insurance denials. Taxpayers, through inflation rebates that reduce public program spending. OBJECTIONS AND RESPONSES: - 'Price caps could reduce investment in new drugs.' Response: The caps here target out-of-pocket patient costs and apply to a defined list of established essential medicines, not new or experimental therapies; manufacturers retain pricing flexibility outside the list. - 'Copay caps may raise premiums for everyone.' Response: This is a real tradeoff. Insulin is a small share of total drug spending, and reduced rationing lowers costly emergency-room and complication treatment, which can offset premium effects. The bill should be paired with an independent cost analysis. - 'Transparency rules create paperwork burden.' Response: Reporting is limited to price increases above inflation on essential drugs, minimizing routine filings. - 'Auto-approval of prior authorizations could increase inappropriate prescribing.' Response: This applies only to maintenance drugs for diagnosed chronic conditions, where ongoing need is established. HONEST LIMITS: This proposal does not directly regulate manufacturer list prices broadly, and the international comparison is a study step rather than immediate negotiation authority. It addresses affordability and access, not the campaign-finance concern one citizen raised, which falls under a different policy area. JURISDICTION: This proposal would fall primarily under the legislative committee with jurisdiction over health and insurance (commonly a Health, or Health and Human Services, committee), with possible referral to a finance or commerce committee for the rebate and insurance-market provisions. Do you support drafting this into formal legislation?
CITIZEN BILL DRAFT · FEDERAL
Insulin and Essential Drug Affordability Act
THE PROBLEM: Citizens in this signal (684 score, 6 voices) describe a consistent crisis: insulin costing $300/month forces rationing and skipped doses, especial
1 vote
0 votes
0 votes
1 total votes
DEEPER CONTEXTSage perspective · Origin · Context
THE SAGE PERSPECTIVE
Informs. Never directs. The vote belongs to you.
Drafted from 6 citizen voices (signal score 684).
WHERE THIS CAME FROM
This poll was opened after 6 similar citizen reports clustered together on the Wire pipeline. THE PROBLEM: Citizens in this signal (684 score, 6 voices) describe a consistent crisis: insulin costing $300/month forces rationing and skipped doses, especially for people on fixed incomes. Citizens note the same drugs cost a fraction of U.S. prices abroad, that insurers deny prescriptions, and that annual price hikes occur without clear justification. One voice raised concern about pharmaceutical campaign donations influencing votes. These signals point to two linked issues: high out-of-pocket drug costs and a lack of transparency in pricing. PROPOSED PROVISIONS: 1. CAP INSULIN COPAYS: Limit out-of-pocket cost for insulin to $35 per month per covered patient across all regulated insurance plans, with no deductible required first. 2. EMERGENCY ACCESS: Establish a pharmacy-level emergency supply program allowing a person to obtain up to a 30-day insulin supply without prior authorization when they would otherwise go without. 3. PRICE TRANSPARENCY: Require manufacturers to publicly justify any list-price increase above the rate of inflation for drugs designated as essential, filing the reason with the relevant health agency. 4. INFLATION-LINKED REBATES: Require manufacturers that raise prices on essential drugs faster than inflation to pay a rebate to the public health program, reducing taxpayer cost. 5. INTERNATIONAL PRICE REFERENCE STUDY: Direct the health agency to publish an annual comparison of U.S. prices for the top 50 essential drugs against prices in peer countries, to inform future negotiation authority. 6. PRIOR-AUTHORIZATION REFORM: Require insurers to respond to prescription prior-authorization requests for essential chronic-condition drugs within 72 hours, and within 24 hours for urgent cases, or the request is automatically approved. 7. ESSENTIAL DRUG LIST: Create a defined, periodically updated list of essential drugs (insulin, inhalers, and other maintenance medications) to which these protections apply. WHO BENEFITS: People with diabetes and other chronic conditions, particularly those on fixed incomes or paying high copays. Patients facing repeated insurance denials. Taxpayers, through inflation rebates that reduce public program spending. OBJECTIONS AND RESPONSES: - 'Price caps could reduce investment in new drugs.' Response: The caps here target out-of-pocket patient costs and apply to a defined list of established essential medicines, not new or experimental therapies; manufacturers retain pricing flexibility outside the list. - 'Copay caps may raise premiums for everyone.' Response: This is a real tradeoff. Insulin is a small share of total drug spending, and reduced rationing lowers costly emergency-room and complication treatment, which can offset premium effects. The bill should be paired with an independent cost analysis. - 'Transparency rules create paperwork burden.' Response: Reporting is limited to price increases above inflation on essential drugs, minimizing routine filings. - 'Auto-approval of prior authorizations could increase inappropriate prescribing.' Response: This applies only to maintenance drugs for diagnosed chronic conditions, where ongoing need is established. HONEST LIMITS: This proposal does not directly regulate manufacturer list prices broadly, and the international comparison is a study step rather than immediate negotiation authority. It addresses affordability and access, not the campaign-finance concern one citizen raised, which falls under a different policy area. JURISDICTION: This proposal would fall primarily under the legislative committee with jurisdiction over health and insurance (commonly a Health, or Health and Human Services, committee), with possible referral to a finance or commerce committee for the rebate and insurance-market provisions. Do you support drafting this into formal legislation?. Sage-labeled theme: HEALTHCARE. Individual Wire report text stays private; only this aggregate lineage is shown.
WHY IT IS ON THE FLOOR
Pharmaceutical and hospital PAC spending heavily influences health-committee votes.
Citizens have elevated healthcare above the synthesis threshold. This proposal reflects their aggregated concern.